Rating: HOLD
| Metric | Value |
|---|---|
| Current Price | $91 |
| Triangulated Fair Value | $84 |
| 12-mo Scenario PWEV | $93 |
| Implied Return | -7% |
| Forward P/E | 16.6x |
| Market Cap | $158B |
| 52-Week Range | $82 – $135 |
Methodology: Valuation triangulated across five independent anchors — Monte Carlo (Student-t + regime switching), an independent DCF, peer re-rating, a sum-of-parts, and a scenario-weighted PWEV. Figures reconciled to Alpha Vantage 2026-06-27. Each chart below sits with the part of the thesis it evidences.
Investment Thesis
The bull case — 'Bull — Re-Rate' (8% weight) — targets $165, +82% vs spot. It needs the multiple to hold or expand.
The dashboard below is the whole argument on one page: spot ($91) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The structural case — 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' (20%) — targets $41, -55% vs spot. This sits below the 52-week low — a genuine structural impairment, not a mild pullback.
Key Debate
P/E Multiple explains 66% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q1): management +0.41 vs analyst floor +0.11 → delta +0.30 (n=14 mgmt / 15 Q&A; 33th pctile across the S&P book, z -0.6).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q1 | +0.41 | +0.11 | +0.30 |
| 2025Q4 | +0.40 | +0.11 | +0.29 |
| 2025Q3 | +0.49 | +0.07 | +0.41 |
| 2025Q2 | +0.41 | +0.02 | +0.39 |
News (last 365d, 1000 articles): avg ticker sentiment +0.13 (bullish 14% / bearish 6%)
Scenario Analysis
The tree runs from a structural 'Structural — Reimbursement / Competition / GLP-1 Procedure Hit' downside ($41) to a 'Bull — Re-Rate' bull case ($165); the probability-weighted blend (PWEV $93) is +3% versus spot.
| Scenario | Probability | Target | Return |
|---|---|---|---|
| Structural — Reimbursement / Competition / GLP-1 Procedure Hit | 20% | $41 | -55% |
| Hospital-Capex / Utilization Recession | 17% | $70 | -23% |
| Base — Procedure Volume + Innovation | 35% | $97 | +7% |
| Growth — New-Product Cycle / Penetration | 20% | $131 | +44% |
| Bull — Re-Rate | 8% | $165 | +82% |
| Probability-Weighted (PWEV) | — | $93 | +3% |
Scenario rationale — what each probability buys (the driver path behind every target):
- Structural — Reimbursement / Competition / GLP-1 Procedure Hit (20%, $41). Structural impairment — reimbursement / competition / GLP-1 procedure hit: earnings AND the multiple compress together. Target sits below the 52-week low by construction. Drivers — implied_target: 40.99; probability: 0.2.
- Hospital-Capex / Utilization Recession (17%, $70). Cyclical downturn — procedure volumes + product-innovation cycle + hospital capital spending weakens for 1–2 years before normalising. Drivers — implied_target: 69.61; probability: 0.17.
- Base — Procedure Volume + Innovation (35%, $97). Mid-cycle — normalised procedure volumes + product-innovation cycle + hospital capital spending; disciplined capital allocation; steady returns. Drivers — implied_target: 96.68; probability: 0.35.
- Growth — New-Product Cycle / Penetration (20%, $131). Upside — new-product cycle + penetration lifts earnings above mid-cycle; the multiple expands modestly. Drivers — implied_target: 130.52; probability: 0.2.
- Bull — Re-Rate (8%, $165). Upside tail — sustained tight conditions or a structural re-rate on new-product cycle + penetration. Drivers — implied_target: 164.84; probability: 0.08.
Valuation Triangulation
Five anchors — but read them with their basis in mind. The Monte Carlo, the DCF terminal, and the peer re-rate all key off a market multiple, so they are not fully independent; only the discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat five numbers as five independent votes.
| Method | Basis | Fair Value | vs Spot |
|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $84 | -8% |
| Peer P/E re-rate | multiple | $95 | +4% |
| Peer EV/Revenue re-rate | multiple | $100 | +10% |
| Scenario PWEV | multiple | $93 | +3% |
| DCF (5-year + terminal) | cash flow + terminal × | $75 | -17% |
| Triangulated (weighted) | — | $84 | -7% |
Monte Carlo — the distribution, not a point
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $84 and 42% of paths finish above spot. The variance decomposition shows the p/e multiple is the dominant swing factor (66% of variance). Value is a multiple bet: fundamentals move the answer far less than the rating does.
DCF — the cash-flow anchor
Independent of the market multiple: a 5-year path, WACC 8.5%, 14x terminal FCF multiple → $75. This anchor is deliberately the heaviest (41%): it is the valuation least hostage to the current multiple regime.
Peer benchmarking — relative value
Against the peer cohort, re-rating to the peer-median forward multiple (P/E 17.28x) implies $95. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Weighted just 12% so the market's mood does not drive the fair value.
Across all anchors the spread is tight (the methods corroborate one another).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Op margin | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|
| Medical Devices & Equipment | $45.1B | 100% | 6% | 24% | 17x | 5% | ESTIMATE |
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | procedure volumes + product-innovation cycle + hospital capital spending |
| net_debt_or_cash_b | -27.24 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.05 |
| div_yield | 0.027 |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | reimbursement / competition / GLP-1 procedure hit |
| upside | new-product cycle + penetration |
Industry Context — Health Devices Tools
This name sits in the Health Devices Tools as a medical_devices. procedure volumes + product-innovation cycle + hospital capital spending Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: TMO (life_science_tools) · ABT (medical_devices) · ISRG (medical_devices) · DHR (life_science_tools) · SYK (medical_devices) · MDT (medical_devices) · BSX (medical_devices) · EW (medical_devices) · IDXX (animal_health) · BDX (medical_devices) · A (life_science_tools) · WAT (life_science_tools) · ZTS (animal_health) · IQV (life_science_tools) · GEHC (medical_devices) · RMD (medical_devices) · DXCM (medical_devices) · VEEV (life_science_tools) · MTD (life_science_tools) · WST (medical_devices) · STE (medical_devices) · ZBH (medical_devices) · COO (medical_devices) · SOLV (medical_devices) · ALGN (medical_devices) · RVTY (medical_devices) · BAX (medical_devices) · PODD (medical_devices) · CRL (life_science_tools) · TECH (life_science_tools)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Reimbursement / Funding / Utilization Reset | 37% | 37% | |
| Mid-Cycle — Procedure & R&D Demand | 35% | 35% | |
| Upside — Innovation / Recovery Re-Rate | 28% | 28% |
On the cluster's key downside — Reimbursement / Funding / Utilization Reset () — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The health_devices_tools cycle is the shared macro driver. Driver — procedure volumes + biopharma R&D/bioprocessing demand + hospital capex Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Model Appendix
DCF — line items
| Year | Revenue | Op income | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $48B | $12B | $2B | $2B | $10B | $9B |
| FY+2 | $50B | $13B | $3B | $2B | $11B | $9B |
| FY+3 | $53B | $14B | $3B | $2B | $11B | $9B |
| FY+4 | $55B | $14B | $3B | $3B | $12B | $9B |
| FY+5 | $57B | $15B | $3B | $3B | $12B | $8B |
| Terminal | — | — | — | — | $12B × 14x | $114B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 5% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 8.5% · Σ PV(FCF) $44B + PV(terminal) $114B = EV $158B; + net cash → equity $130B ÷ diluted shares 1.74B = $75/share (exit-multiple terminal).
- Gordon (perpetuity-growth) terminal at 2.5% → $89/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
- Incremental ROIC on the forecast capex ≈ 19% vs WACC 8% → above WACC — the build is value-creative.
Peer set
| Peer | EV/Rev | Fwd P/E | Growth | Op margin |
|---|---|---|---|---|
| ISRG | 12.95x | 38.61x | 6% | 31% |
| SYK | 5.26x | 21.05x | 6% | 18% |
| MDT | 3.35x | 13.51x | 6% | 22% |
| BSX | 3.651x | 13.16x | 6% | 21% |
| Median | 4.4555x | 17.28x | — | — |
Peer-median fwd P/E → $95; EV/Rev → $100.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $75 | 41% | $31 |
| Scenario PWEV | $93 | 29% | $27 |
| Monte Carlo median | $84 | 18% | $15 |
| Peer P/E | $95 | 12% | $11 |
| Triangulated | — | 100% | $84 |
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 9.8x | 11.9x | 14.0x | 16.1x | 18.2x |
|---|---|---|---|---|---|
| 6% | $61 | $72 | $83 | $93 | $104 |
| 8% | $58 | $68 | $79 | $89 | $99 |
| 8% | $55 | $65 | $75 | $85 | $95 |
| 10% | $53 | $62 | $71 | $81 | $90 |
| 10% | $50 | $59 | $68 | $77 | $86 |
DCF/share — revenue CAGR Δ × op-margin Δ
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $56 | $60 | $65 | $70 | $74 |
| -1.5pp | $60 | $65 | $70 | $75 | $80 |
| +0.0pp | $64 | $70 | $75 | $80 | $86 |
| +1.5pp | $69 | $75 | $80 | $86 | $92 |
| +3.0pp | $74 | $80 | $86 | $92 | $98 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Revenue CAGR ±3pp | $65 | $86 | $21 |
| Op margin ±3pp | $64 | $86 | $21 |
| Terminal × ±15% | $65 | $85 | $20 |
| WACC ±1pp | $71 | $79 | $7 |
| FCF conversion ±10% | $75 | $75 | $0 |
Company lever — SoP/share vs Medical Devices & Equipment multiple (AI re-rating) (base 17x)
| Multiple | 11.9x | 14.4x | 17.0x | 19.5x | 22.1x |
|---|---|---|---|---|---|
| SoP/share | $292 | $357 | $424 | $489 | $557 |
Load-Bearing Assumptions
DCF: WACC 8%, terminal multiple 14×, FY+5 revenue $57B. Triangulation leans 41% on DCF, 29% on PWEV.
Reasons the Thesis Could Fail (Falsifiable)
The valuation is multiple-dependent (66% of variance); a de-rating toward the DCF anchor ($75) implies -17%.
Fact / Inference / Speculation
- FACT: Spot $91; 52-week range $82–$135; engine rating HOLD; base-case target $93 (+3%).
- INFERENCE: Triangulated FV $84 (-7%). P/E Multiple explains 66% of Monte Carlo outcome variance — i.e. value is set by the multiple the market will pay, a rate/sentiment regime bet as much as an earnings bet.
- SPECULATION: At current prices the embedded bet is that the multiple holds or expands — P/E Multiple carries 66% of outcome variance.
Recommendation: HOLD
Balanced: triangulated fair value $84 (-7% vs spot); the outcome hinges on P/E Multiple. The debate is P/E Multiple (66% of variance) — fundamentally a multiple/regime call. SBC runs —M TTM (disclosed in the appendix).